Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03044730
Title Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Northwestern University
Indications

breast cancer

Her2-receptor negative breast cancer

triple-receptor negative breast cancer

Therapies

Capecitabine + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.